Short report: Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?

Página do item simplificado
dc.contributor.authorAmato V.S.
dc.contributor.authorTuon F.F.
dc.contributor.authorCamargo R.A.
dc.contributor.authorSouza R.M.
dc.contributor.authorSantos C.R.
dc.contributor.authorNicodemo A.C.
dc.date.accessioned2024-03-13T01:10:14Z
dc.date.available2024-03-13T01:10:14Z
dc.date.issued2011
dc.description.abstractLiposomal amphotericin B has been used as an alternative treatment of mucosal leishmaniasis, but the optimal dose is not established. We retrospectively reviewed the clinical outcome of eight patients with mucosal leishmaniasis treated with liposomal amphotericin B. The mean total dose was 35 mg/kg (range 24-50 mg/kg), which resulted in the healing of all the lesions in all patients and no recurrences were observed during the follow-up period (mean 25 months; range 7-40 months). Copyright © 2011 by The American Society of Tropical Medicine and Hygiene.
dc.description.firstpage818
dc.description.issuenumber5
dc.description.lastpage819
dc.description.volume85
dc.identifier.doi10.4269/ajtmh.2011.11-0287
dc.identifier.issn0002-9637
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/36930
dc.relation.ispartofAmerican Journal of Tropical Medicine and Hygiene
dc.rightsAcesso Aberto
dc.titleShort report: Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?
dc.typeArtigo
local.scopus.citations29
local.scopus.eid2-s2.0-81155134256
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=81155134256&origin=inward
Arquivos
Coleções
Artigos de periódico